Comparison of agar dilution and broth microdilution methods for Clostridium difficile antimicrobial susceptibility testing.
In this study, the performance of the broth microdilution (BMD) method for testing the antimicrobial susceptibility of Clostridium difficile in comparison with the agar dilution (AD) method used by the Clinical and Laboratory Standards Institute (CLSI) was evaluated. In total, 70 non-duplicate C. difficile clinical isolates were used in this study. The minimum inhibitory concentrations (MICs) of clindamycin, moxifloxacin, metronidazole and vancomycin were examined using AD and BMD. The results showed that BMD is acceptable for routine antimicrobial susceptibility testing of C. difficile as its performance was comparable with that of the AD method. In addition, it was noted that metronidazole- and vancomycin-resistant isolates are extremely rare in Japan.
Department of Microbiology and Immunology, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Gene
G
Igawa
Department of Microbiology and Immunology, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Mika
M
Casey
Department of Clinical Laboratory, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan; Department of Infection Control and Prevention, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan.
Etsuko
E
Sawabe
Department of Infection Control and Prevention, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan.
Yoko
Y
Nukui
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.
Shu
S
Okugawa
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.
Kyoji
K
Moriya
Department of Infection Control and Prevention, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan.
Ryuji
R
Koike
Department of Clinical Laboratory, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan.
Shuji
S
Tohda
Department of Microbiology and Immunology, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan; Department of Infection Control and Prevention, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: r-saito.mi@tmd.ac.jp.
Ryoichi
R
Saito
D000362:Agar; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002981:Clindamycin / Q000494:pharmacology; D016360:Clostridioides difficile / Q000187:drug effects*; D024841:Fluoroquinolones / Q000494:pharmacology; D007564:Japan; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests / Q000379:methods*; D000077266:Moxifloxacin; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D008795:Metronidazole; D002981:Clindamycin; D014640:Vancomycin; D000362:Agar; D000077266:Moxifloxacin
Agar dilution; Broth microdilution; Clostridium difficile; Japan; Metronidazole; Vancomycin